Publication:
Phase I trial of a Plasmodium vivax CS derived synthetic peptide vaccine candidate

Simple item page
dc.contributor.authorHerrera, Sócrates
dc.date.accessioned2024-02-15T20:43:39Z
dc.date.available2024-02-15T20:43:39Z
dc.date.issued2001
dc.description1 documento
dc.description.abstractThis project was aimed at conducting a Phase 1 clinical trial to assess the safety, immunogenicity and protective efficacy of synthetic peptides derived from different regions of the P. vívax es protein in human volunteers. The trial was proposed on the bases of previous studies that had allowed us to partially characterize immunologically the protein . We had study the P . vívax CS antigenicity in humans and monkeys and had defined B, Th and eTL epitopes (refs) . Additionally we had conducted studies on the immunogenicity of peptides derived from this protein both in rodents and in non-human primates using bench quality synthetic peptides . Because of the minimal requirement of the vaccine quality for human use , we proposed to produce 3 long synthetic peptides under GLP conditions and to test them in young human naive volunteers . Although this objective was approved , Colciencias recommended that a further pre-clinical trial in monkeys must be performed with the new GLP quality vaccines . This recommendation was accepted by the group and is reported here.eng
dc.format.extent79 p.
dc.format.mimetypeapplication/pdf
dc.identifier.urihttps://repositorio.minciencias.gov.co/handle/20.500.14143/50766
dc.language.isospa
dc.publisherUniversidad del Valle
dc.publisherColciencias
dc.publisher.placeCali
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.creativecommonsAtribución 4.0 Internacional (CC BY 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.lembProyectos de investigación
dc.subject.lembBiología molecular
dc.subject.lembInmunología
dc.subject.proposalParásitosspa
dc.subject.proposalExperimentos clínicosspa
dc.subject.proposalPéptidospa
dc.titlePhase I trial of a Plasmodium vivax CS derived synthetic peptide vaccine candidateeng
dc.typeInforme de investigación
dc.type.coarhttp://purl.org/coar/resource_type/c_18ws
dc.type.contentText
dc.type.driverinfo:eu-repo/semantics/report
dc.type.redcolhttp://purl.org/redcol/resource_type/INF
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dcterms.audienceEstudiantes, Profesores, Comunidad científica colombiana, etc.spa
dspace.entity.typePublication
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2
oaire.awardnumber11060506397
oaire.awardtitlePhase I trial of a Plasmodium vivax CS derived synthetic peptide vaccine candidate
oaire.funderidentifier.colciencias399-97
oaire.fundernameDepartamento Administrativo de Ciencia, Tecnología e Innovación [CO] Colciencias
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
1106-05-063-97 INFORME FINAL.pdf
Size:
40.23 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
15.18 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Informes Finales de Proyectos de Investigación